Compare James Hardie Industries plc. Ordinary Shares (JHX) vs Natera Inc. Common Stock (NTRA) Price & Performance

James Hardie Industries (JHX) trades at $24.67, down 0.36% with a bearish technical outlook. The stock shows mixed fundamentals with a high P/E ratio of 112.14 but strong revenue growth from $3.88B to $5.4B projected. Recent earnings beat expectations in Q2 2026, and the company completed strategic divestitures including the $980M Fermacell sale to Holcim. Analyst sentiment remains positive with 70.59% buy ratings and a $34 consensus price target representing 38% upside potential.

JHX presents a growth story with expanding revenues but faces profitability compression as net margins decline from 10.93% to 2.69%. The stock's high valuation multiples require strong execution to justify. Key risks include integration challenges from recent acquisitions, rising debt levels, and housing market sensitivity. Institutional ownership shows mixed signals with State Street reducing its position while short interest increased 47.8% in September 2026.

NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.

NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.